Targeting the BRAF V600E Mutation in Colon Cancer

  • The BREAKWATER trial showed that combining targeted therapy with chemotherapy, specifically encorafenib plus cetuximab plus mFOLFOX6, significantly improved outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer, a group that has historically faced aggressive disease and limited outcomes.
  • The combination of encorafenib, cetuximab, and mFOLFOX6 improved tumor response, progression-free survival, and overall survival compared with standard care. These results support the use of this regimen as a new first-line standard for appropriate patients.
  • Ongoing studies are evaluating targeted therapy in combination with FOLFIRI in Cohort 3 of the BREAKWATER study.
  • Several questions remain, including the best sequencing of therapy, how to manage resistance, how to treat patients with overlapping MSI-H disease, and how to balance survival benefit with quality of life.

For patients with metastatic colorectal cancer, treatment decisions increasingly depend on the genetic features of the tumor, and one of the most studied mutations is BRAF V600E. The BREAKWATER trial represents an important step forward for patients with this mutation, which has historically been associated with more aggressive disease and, consequently, worse outcomes. The most recent data from the trial will add important context to help oncologists pick the best treatment combinations for patients.

BREAKWATER showed that combining targeted therapy with chemotherapy, specifically encorafenib plus cetuximab plus mFOLFOX6, significantly improved outcomes compared with standard chemotherapy-based treatment.

“BRAF is present in about 9% of patients with metastatic colorectal cancer,” Dr. Cathy Eng, a medical oncologist at Vanderbilt Ingram Cancer Center, tells SurvivorNet Connect. “Historically, with standard chemotherapy, their overall survival is only 12 to 14 months. With the use of encorafenib, a BRAF inhibitor, plus EGFR therapy (in this case, Cetuximab) in combination with chemotherapy, the median survival has improved to 30.3 months.”

Based on these results, this regimen has become a new first-line standard of care for patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. Importantly, ongoing studies are evaluating targeted therapy in combination with FOLFIRI in Cohort 3 of the BREAKWATER study.

BREAKWATER Shows Significant Benefit

The BRAF gene is part of a signaling pathway that promotes cancer cell growth and survival when mutated. When the common V600E mutation is present, this pathway can become overactive. BREAKWATER tested whether directly targeting this biology from the beginning of treatment could improve outcomes.

BREAKWATER was a global, randomized, phase 3 clinical trial. It enrolled 637 patients with previously untreated metastatic colorectal cancer whose tumors carried the BRAF V600E mutation.

Patients were assigned to one of three treatment groups:

  • Encorafenib plus cetuximab, also called EC
  • Encorafenib plus cetuximab plus mFOLFOX6, also called EC+mFOLFOX6
  • Standard of care chemotherapy, chosen by the treating investigator

The standard-of-care group could receive chemotherapy regimens such as mFOLFOX6, FOLFOXIRI, or CAPOX, with or without bevacizumab. Note that the EC-alone arm was closed after a protocol amendment, so the main comparison became EC+mFOLFOX6 versus standard of care.

The BREAKWATER trial met its major goals. Patients who received encorafenib plus cetuximab plus mFOLFOX6 had better outcomes than those who received standard-of-care treatment:

  • The overall response rate was 60.9% with EC+mFOLFOX6, compared with 40.0% with standard care.
  • The median progression-free survival was 12.8 months with EC+mFOLFOX6, compared with 7.1 months with standard care.
  • The median overall survival was 30.3 months with EC+mFOLFOX6, compared with 15.1 months with standard care.

These results are clinically meaningful. In particular, the improvement in overall survival is striking for a patient population that has historically had limited outcomes.

The treatment was not without side effects. Serious adverse events occurred in 46.1% of patients receiving EC+mFOLFOX6, compared with 38.9% of patients receiving standard care. However, the safety findings were described as consistent with the known toxicities of the individual drugs.

A New Standard & Ongoing Research

The most important finding from BREAKWATER is the survival benefit. Historically, patients with BRAF V600E-mutant metastatic colorectal cancer had much worse outcomes than patients with BRAF wild-type disease.  

“The average survival for any metastatic non-BRAF patient historically is anywhere between 32 and 36 months. So now we’re finally getting these patients that were originally believed to be poor prognostic patients, really almost up to the average median survival of a non-BRAF patient,” Dr. Eng says. 

Another strength is that the benefit appeared consistent across important patient subgroups, including patients with liver metastases, right-sided tumors, involvement of three or more organs, and different performance status levels.

Although BREAKWATER is a landmark trial, it is still important to interpret the results carefully. The control arm was heterogeneous, so patients in the standard-of-care group could receive different chemotherapy regimens, including mFOLFOX6, FOLFOXIRI, or CAPOX, with or without bevacizumab. This reflects real-world practice, but it also makes interpretation more complex.

A key question is how many patients in the standard-care group received FOLFOXIRI plus bevacizumab, which has previously been considered one of the most active options for fit patients with BRAF V600E-mutant metastatic colorectal cancer.

If many control patients received less intensive doublet chemotherapy, the apparent benefit of EC+mFOLFOX6 may appear larger than it would against the most aggressive chemotherapy comparator.

The closure of the EC-alone arm also limits what we can conclude about the exact contribution of chemotherapy. The available descriptive results suggest that adding chemotherapy improved outcomes, but the EC-alone comparison was not powered for a definitive statistical conclusion.

One of the major debates is how EC+mFOLFOX6 compares with FOLFOXIRI plus bevacizumab. Before BREAKWATER, FOLFOXIRI plus bevacizumab was often considered a strong first-line option for fit patients with aggressive BRAF V600E-mutant disease. However, there has not been a direct head-to-head trial comparing FOLFOXIRI plus bevacizumab against EC+mFOLFOX6.

Future Directions

The next challenge is understanding why some tumors eventually become resistant to BRAF- and EGFR-targeted therapy.

Resistance may occur through reactivation of the MAPK pathway, new RAS mutations, BRAF amplification, MET amplification, or changes in the PI3K pathway. Several research strategies are being explored to delay or overcome this resistance.

Finally, the high tumor response rate seen in BREAKWATER raises the question of whether this regimen could help some patients with initially unresectable metastatic disease become candidates for surgery. This idea is promising, but it was not a primary endpoint of the trial and needs further study.

“Colon cancer is a common cancer. We are now able to, for some patients, identify what we call actionable mutations or specific mutations that have drugs created to potentially block them or focus on that molecular target,” Dr. Eng adds. “… obviously, there are a lot of other drugs we would like to target. We’re looking forward to a lot of the other possibilities that pharmaceutical companies are developing.”

Dr. Kaique Filardi is a board-certified general surgeon and gastrointestinal (GI) surgeon from the University of São Paulo. He is currently an oncologic surgery research fellow at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, and serves as a teaching assistant in the Principles and Practice of Clinical Research (PPCR) program at Harvard Medical School.

Read More